Abnormal uterine bleeding can severely affect the quality of life for women. Following menstruation the endometrium must adequately repair to limit and stop bleeding. Abnormal uterine bleeding may result from incorrect or inadequate endometrial repair following menstruation. Previous studies have shown an important contribution of activin to skin wound healing, with severely delayed wound repair observed in animals transgenically induced to over-express activin's natural inhibitor, follistatin. Activin subunits have also been identified within human endometrium; however their role in endometrial repair is unknown. We assessed the contribution of activin to endometrial repair following menses using a human in vitro cell wounding method, and our well-characterised mouse model of endometrial breakdown and repair applied to mice over-expressing follistatin. Endometrial repair after menses is initiated with re-epithelialisation of the uterine surface. To mimic this repair we utilised a human endometrial epithelial cell line (ECC-1) and demonstrated significant stimulation of wound closure following activin A administration, and attenuation of this response by addition of follistatin. Immunolocalisation of activin subunits, βA and βB, in control endometrium from the mouse model demonstrated specific epithelial and stromal localisation and some leukocyte staining (βA) around sites of endometrial repair, suggestive of a role for activin in this process. Follistatin over-expressing animals had significantly higher circulating follistatin levels than wild-type littermates. There was a significant delay in endometrial repair following breakdown in follistatin transgenic animals compared to control animals. This study demonstrates for the first time, a functional role for activin in endometrial repair following menses.
Introduction
Knowledge of the molecular mechanisms underlying menstruation and menstrual disorders is limited, largely due to a lack of suitable animal models for study. Our working hypothesis is that at least some uterine bleeding problems result from incorrect or inadequate endometrial restoration after menses. The endometrial restoration which occurs following menses has many similarities with wound healing events. In general terms, wound healing is said to occur in three phases; inflammation, tissue formation and tissue remodelling (for review see (1) . Within the uterus, the initial tissue injury or endometrial breakdown that occurs during menstruation has been well characterised for its cascade of inflammatory responses including a massive recruitment of leukocytes into the endometrium (2-4). Thereafter rapid re-epithelialisation of the uterine surface occurs within the first 48h after the first two menstrual days (5) followed closely by renewal of the stromal compartment.
During healing of skin wounds, the importance of members of the transforming growth factor beta (TGFβ) superfamily has been demonstrated using a number of knockout and transgenic animals (for review see (6). In particular the activins, a TGFβ subfamily, and the focus of this study, have been shown to have novel roles in both inflammation and repair (7, 8).
All forms of activin are dimers of two monomeric proteins (β subunits) joined by a disulfide linkage; the best studied are the homodimeric activins A (βAβA) and B (βBβB) and heterodimeric activin AB (βAβB) (9). Subunit genes of βC and βE have also been described in human; however considerably less is known about their function or activity in vivo. Activin A, B and AB exert their biological effects through binding to either a type I or type II receptor. The activin receptors include two type 1, activin receptor (ActR) 1A and ActRIB, and two type II receptors, ActRIIA and ActRIIB (10). In simplified terms, activin binding of a type II receptor results in the recruitment, phosphorylation and activation of a type I receptor which in turn phosphorylates intracellular receptor substrates, Smads 2 and 3, to regulate transcription of target genes (11, 12).
Follistatin is another functionally related protein that binds and neutralises the activity of several TGFβ superfamily members. It is a secreted glycoprotein capable of binding activins with picomolar affinity and inhibiting their biological function (for review see (13) (14) (15) .
Follistatin inhibits the function of activins by preventing their binding to the type II receptor (14, 16), as well as accelerating their clearance by endocytotic degradation (17). Two isoforms of follistatin resulting from alternative splicing have been described (18-20); FS-315, and the shorter FS-288. Both isoforms have a similar affinity for activin. However whilst FS-315 is the more abundant of the two isoforms, FS-288 is said to have a higher local availability as a result of its greater affinity for heparan sulphate proteogylcans on cell surfaces (20, 21).
A number of in vivo studies support a contribution of endogenous activins to wound healing (7, 8, 22) . A recent study (8) utilised a mouse over-expressing FS-315 under a human keratin 14 promoter, which resulted in over-expression of FS in the epidermis (8). These follistatin transgenic mice showed impaired wound healing (8), which was in direct contrast to that seen in mice overexpressing activin βA under the same promoter, in which the rate of wound healing was enhanced (7). In a separate study, when the expression pattern of activin was assessed after injury in the skin, high levels of both activin A and B mRNA expression were observed within the first 7 days after wounding (22).
Moreover in situ hybridisation studies demonstrated expression of activin A in the granulation (scar) tissue below the wound and activin B in the hyperproliferative epithelium at the wound edge (22). All this evidence demonstrates that activins play important roles in wound healing.
The aim of the present study was to determine whether activins are likewise important for endometrial repair/restoration. Initially we examined the contribution of activin A to human endometrial epithelial wound closure utilising an in vitro wounding assay. Secondly, we applied our well characterised mouse model of endometrial breakdown and repair (23-26) to mice over-expressing follistatin (8) to examine the in vivo importance of activin to endometrial repair.
Materials and Methods

Endometrial epithelial cell lines
We used a human endometrial epithelial cell line (ECC1), (a gift from Professor Bruce Lessey Center for Women's Medicine, Division of Reproductive Endocrinology and Infertility, Greenville Hospital System, Greenville, South Carolina). which has been well-characterised previously (27-29). Cells were grown in a 1:1 mixture of DMEM and Ham's F12 (Multicel Thermo Electron, Melbourne, Australia) supplemented with 1% L-glutamine (Multicel Thermo Electron) and 1% penicillin, streptomycin and fungiozone (PSF, Commonwealth Serum Laboratories, Melbourne Australia) and containing 10% fetal calf serum (FCS, Trace Biosciences, NSW, Australia).
Wounding assay
Cells were plated at 1 million cells per well of a 6-well plate (Nunc, Rockford, IL, USA) and grown to over-confluence for 72 h. Cells were then serum-starved in the same media containing 2% charcoal stripped FCS (csFCS) for 24h before wounding was carried out using vacuum suction and a Prot/Elec pipette tip (Bio-rad, Hercules, CA, USA). The initial day of wounding was denoted as day 0, and cell wounds were photographed using a Leica DC300 camera and Leica IM50 software (Leica Microsystems, Germany) on that day and subsequently every 24 h for up to 6 days. Medium was substituted with PBS without calcium and magnesium (PBS-) for photographing, and fresh medium was then added. To assess differences in repair, the area of each cell wound was assessed using analySIS Soft Imaging Software on day 0 and on each subsequent day, with data expressed as percent repair compared to day 0. For each experiment (total of 3), 4-6 wounds were assessed per treatment, with data presented as mean ± SEM. Under control conditions the average intra-assay % CV was 16.4%, and the inter-assay % CV was 18% with some variation between days (depending whether cells were undergoing active repair or were at the end stages of repair). Treatments used included epidermal growth factor (EGF; Sigma, MO, USA) at a final concentration of 50 ng/ml, activin A (ActA; R&D systems, MN, USA) at a final concentration of 50 ng/ml made up in 0.1% bovine serum albumin (bSA; Sigma), or follistatin (purified from bovine follicular fluid) (30) at a final concentration of 200ng/ml plus activin A (50ng/ml), with 0.1% (activin A alone control) or 0.15% bSA (FS + activin A control) used for control wells. These doses were chosen following preliminary experiments and from published work (31, 32). The 'mouse model of endometrial breakdown and repair' Endometrial breakdown and repair was induced in mice according to a standard protocol as previously described (23). Briefly, under xylazine/ketamine-induced anesthesia, mice were ovariectomized 7 days prior to the first of three daily subcutaneous (s.c) injections of 100 ng 17β-estradiol (Sigma) in arachis oil at approximately 09:00h. After resting the mice for 3 days, progesterone (P) implants were inserted s.c into the back of each mouse.
Animals
Simultaneously the mice received a single injection s.c of P in arachis oil, and an injection of 5 ng 17β-estradiol in arachis oil was given at approximately 09:00h on that and the subsequent two days. At approximately 11:00h on the day of the final 17β-estradiol injection, 20 μl of sesame oil was injected into the lumen of the right uterine horn of each mouse to induce decidualization. The left horn remained untreated as a control. The P implants were removed 48 h after oil injection and mice were killed 24 and 48 h after P removal. Uteri were cleaned of fat and weighed. Tissue was cut into pieces and fixed in Carnoy's fixative for 4 hours or phosphatebuffered formalin overnight and processed to wax in an orientation that would provide cross-sections. Any mouse in which the oiltreated horn had not decidualized (as evidenced by weight ≥ 400% of the untreated contralateral horn, and histological assessment) was excluded from the study.
Assessment of uterine weight
In the original study in which the FSTG mice were described, it was noted that these animals were macroscopically abnormal, having large ears and long tails (relative to their body size), rough irregular coats, eye problems, and were smaller in size than WT animals, according to body weight (8). To assess any effect of the FS transgene on uterine weight, which may result from excess follistatin, the non-stimulated horn from FSTG (n= 11) and WT (n= 3) animals was collected at the time of death and weighed. The non-stimulated horn was chosen in preference to the stimulated horn to overcome the variability in uterine weight associated with stage of endometrial breakdown and repair (for example a horn undergoing active breakdown will be considerably heavier than one collected after complete repair).
Ex-vivo uterine culture
To identify differences in follistatin and/or activin A secretion from the uteri of FSTG compared to WT animals, an ex vivo culture system was set up. To ensure data were not confounded by variables associated with endometrial breakdown and repair (eg leukocyte infiltration), non-stimulated uterine horns were used for culture. Each uterine horn was divided into three portions, and the weight of each portion was recorded (4.5 ± 0.6 mg, mean ± SEM) before each was finely chopped using a razor blade under sterile conditions. The fragments from each portion were then placed into three separate wells of a 24-well tissue culture dish and cultured in RPMI-1640 (Sigma) supplemented with 1% L-glutamine and 1% PSF with either no serum, 2% fetal calf serum, or 10% FCS. Conditioned media were collected at 24 h and analysed for follistatin and activin A levels as described below. Results were expressed per milligram (mg) of tissue.
Follistatin measurement
Mouse serum and conditioned media follistatin (FS) concentrations were measured using a discontinuous radioimmunoassay as described previously (33). Serum was collected from animals that had been taken through the mouse model of endometrial breakdown and repair, and was collected at the time of death. For the serum samples, the average intra-assay % coefficient of variation (CV) was 8.1%, the intra-assay % CV was 5.8% (n=2 assays) and the limit of detection was <0.88 ng/ml. Media samples and standards were diluted in unconditioned media. The average intra-assay % CV was 8.0%, the inter-assay % CV was 9.2% (n=2 assays) and the limit of detection was <1.73 ng/ml.
Activin A measurement
Activin A was measured in mouse serum and in tissue culture medium using a specific enzyme linked immunosorbent assay (ELISA) (34) according to the manufacturer's instructions (Oxford Bio-Innovations, Oxfordshire, UK) with some modifications as described previously (33). Serum was collected from animals that had been taken through the mouse model of endometrial breakdown and repair, and was collected at the time of death. All serum samples were measured in a single plate and the intra-assay % CV was 8.2%. Media samples and standards were diluted in unconditioned media without serum. The average intra-plate % CV was 9.9%, and the inter-plate % CV was 6.0% (n=4 plates). The limit of detection for the assay was 0.01ng/ml.
Immunohistochemistry for inhibin/activin subunits Inhibin/activin ßA, and ßB subunits were immunolocalised using affinity purified rabbit polyclonal antibodies raised against the individual inhibin subunits (anti-porcine inhibin ßA and anti-human inhibin ßB ; (kind gifts from Prof. Wylie Vale, La Jolla, CA, USA; (35)), as previously described (36). Mouse ovary was included as a positive control. In brief, 5 μm cross sections of formalin-fixed uterine tissue from FSTG and WT animals were de-paraffinised and hydrated by processing sections through Histosol and a graded series of ethanol to distilled (d)H 2 O. Microwave antigen retrieval was performed (5 min HIGH, 5 min LOW in a 1 kW microwave oven, followed by 20-min cooling), and endogenous peroxidase activity blocked with aqueous 3% H 2 O 2 . Primary antibodies were applied at 2 μg/ml in a nonimmune block containing 20% goat serum and 0.1% Tween-20 in TBS. Negative controls were performed by substitution of primary antibody with 2 μg/ml rabbit IgG (DAKO, Glostrup, Denmark). Antibody binding was thereafter detected by sequential application of conjugate for 1 h at room temperature, with DAB (DAKO) forming an insoluble brown precipitate. Tissue sections were counterstained with Harris's hematoxylin (Sigma), dehydrated, and mounted with DPX (BDH Laboratory supplies, Poole, UK) mounting medium.
Assessment
of extent of tissue breakdown/restoration Cross sections of formalin-and Carnoy'sfixed uterine tissue from FSTG and WT animals were de-paraffinised and hydrated by processing sections through Histosol (Sigma) and a graded series of ethanol to distilled (d)H2O. The hydrated sections were stained with hematoxylin and eosin using standard procedures. Stained sections were dehydrated and mounted under coverslips using DPX mounting medium.
Sections were then examined for extent of tissue breakdown and/or repair and analyzed using a scoring system from 1-5 as previously described (25), where 1= intact decidualized tissue, 3= complete breakdown and 5= complete repair. To increase n values for the control group, control animals from previous studies (25, 26) were included in the final evaluation after we determined that they were not different from those in the present study. For each animal, 2-4 sections from different areas of the uterus were assessed and scored to determine the intra-animal variation. Inter-animal variation was determined by calculation and comparison of the mean score for each animal. All tissue sections were scored blind by two independent observers.
Statistical analysis
After testing for normal distribution, statistical analysis was performed using a one way ANOVA followed by a Dunnett's multiple comparison post hoc test (p< 0.05 was taken as significant). To assess differences in morphological stage for the in vivo study the non-parametric, Mann-Whitney test was performed for FSTG vs WT. All statistical analysis was carried out using PRISM version 3.00 for Windows. All data are presented as mean ± SEM.
Results
In vitro studies using cell line Wounding assay: Activin A increases repair of ECC-1 cell wounds At a dose of 50 ng/ml, activin A significantly (p<0.05 -p<0.01) increased repair of wounds created in ECC-1 monolayers between days 2-6 compared to control at each time point ( Figure 1A ) Lower doses (0.1-10 ng/ml) did not significantly stimulate repair. EGF (50 ng/ml) also significantly (p<0.01) increased repair of ECC-1 wounds between days 1-6 compared to control ( Figure 1A ).
Follistatin attenuates the activin A effect on ECC-1 wound repair
Addition of FS + activin A significantly (p<0.0001) attenuated the activin A response from days 2-6 culture ( Figure 1B) . FS treatment alone was not significantly different to control (data not shown).
In vivo studies in mice
Uterine weight No significant difference in uterine (nonstimulated) weight (expressed as percentage (%) of total body weight) was detected (0.070 ± 0.01% for FSTG, n=11 vs 0.066 ± 0.02% for WT, n=3).
Serum follistatin and activin A levels in FSTG and WT mice
Circulating follistatin levels ranged from 13-65 ng/ml (33.3 ± 3.8 ng/ml) in the FSTG mice (n=14 animals) (Figure 2A ). In comparison, follistatin levels in WT animals were significantly lower (p<0.01) ranging from 4-13 ng/ml (7.07 ± 1.8 ng/ml, n=5 animals).
Circulating activin A levels ranged from 0.03-0.3ng/ml (mean±SEM 0.1±0.03 ng/ml) in the same FSTG mice (n=14) ( Figure 2B ). These were not different from levels in the WT mice (0.08 -0.14ng/ml, mean±SEM, 0.13±0.02ng/ml, n=5 animals).
Ex vivo uterine secretion of follistatin and activin A.
An ex vivo serum free culture system was used to assess the uterine-specific secretion of follistatin and activin A from FSTG compared to WT mice. Uterine secretion of follistatin over 24 h from FSTG was 1.7 ± 0.09 ng/mg tissue (n=5) compared to 1.64 ± 0.46 ng/mg (n=5) for WT ( Figure 3A) . Ex-vivo uterine secretion of activin A from the same samples was 0.052 ± 0.01 ng/ml (n=5) for FSTG and 0.060 ± 0.03 ng/ml (n=5) for WT ( Figure 3B ). No significant difference was detected in follistatin or activin A secretion between the two groups.
Activin
βA and βB subunit immunohistochemistry Activin βA subunit staining was assessed in the late breakdown stage in WT animals ( Figure 4A ) and during endometrial repair in both WT ( Figure 4B ) and FSTG animals ( Figure 4C, D) . Staining patterns did not differ greatly between FSTG and WT animals. When breakdown was occurring in the decidual zone, βA immunostaining was observed in glandular epithelium in the basal compartment of stroma which had not decidualised and was thus not breaking down ( Figure 4A ). Strong staining was also identified in the layer of stromal cells within this same basal region of the endometrium between the breakdown zone and myometrium ( Figure 4A ). Once endometrial restoration was underway, pale βA staining was evident within the luminal epithelium ( Figure 4B , C, D), with some sections also displaying strong stromal staining adjacent to sites where reepithelialisation was occurring ( Figure 4C ). Strong punctuate staining, likely to be leukocyte staining, was evident in most tissues undergoing repair ( Figure 4B, C, D) . The negative controls were free of stain ( Figure  4E ).
Activin βB subunit staining was likewise assessed in the late stage of breakdown in WT animals ( Figure 4F ) and during endometrial repair in both WT ( Figure 5H, I ) and FSTG animals ( Figure 4G ). Similar to βA, staining patterns did not differ greatly between FSTG and WT animals. During late breakdown, βB immunostaining was observed in a similar pattern to that of βA, with both glandular and basal stromal cell staining apparent ( Figure  4F ). Similarly again, βB staining was evident within the luminal epithelium as endometrial restoration was underway ( Figure 4G, H, I ) with varying levels of intensity. In fully restored endometrium intense glandular staining was observed ( Figure 4I ). In contrast to βA, no leukocyte staining was evident for βB. The negative controls were clear ( Figure  4J ).
Endometrial restoration is altered in follistatin transgenic mice
At the time of endometrial breakdown, no significant difference between groups was identified (data not shown). For endometrial repair assessment, as sections for scoring were available from only 2 WT littermate animals, scores from other control animals (not littermates, but the same genetic background) were included (total n=15). Scoring of the tissue demonstrated that in the FSTG group (n=8), only 52% of tissue had full repaired (stage 5), 38% were undergoing early repair (stage 4) and 10% were still breaking down (stage 3) ( Figure 5 ). This was significantly different (p<0.05) than the WT group where 79% of sections had fully repaired (stage 5), 19% were undergoing early repair (stage 4) and 2% of sections were still breaking down (stage 3).
Discussion
This is the first study to demonstrate a likely role for activin in endometrial restoration following menstruation, using both a human endometrial epithelial cell line wounding model, and a mouse model mimicking events following menstruation. In the cell wounding model, activin significantly stimulated repair, whilst in mice transgenic for follistatin (with up to 10x higher circulating follistatin levels than their WT littermates) we report significantly delayed endometrial repair.
The contribution of activins and other TGFβ superfamily members to inflammation and wound healing in other tissue types has been well studied (for review see (37), particularly in the skin. Within normal skin, both activin βA and βB subunits are barely detectable; however both are strongly induced after injury (22).
In accord, transgenic mice overexpressing the βA chain in the epidermis demonstrate a strongly enhanced healing rate of full-thickness wounds (7), whilst transgenic mice over-expressing the activin antagonist follistatin in the epidermis, demonstrate impaired wound healing (8). Importantly, these studies in transgenic animals also demonstrated the contribution of activin to scarring with significantly extended scar tissue observed in the βA transgenic animals (unpublished data cited in (37), compared to reduced areas of scar tissue in the follistatin transgenic animals (8).
Although some features of wound healing are common to all tissues, there are important differences between tissues, particularly between skin and mucosal repair, and thus not all aspects of repair in tissues such as the skin may be applicable to endometrial repair. It is well established that healing within the endometrium is scar-free (for review see (38). Since this is a phenomenon only observed elsewhere in fetal development (39, 40) and oral wounds (41), it is expected that wound healing events in the endometrium may have important differences from those in tissues that scar. This study however demonstrates a similarity of endometrial healing after menses and skin wound healing in terms of the contribution of activin. Both in vivo and in vitro data presented here suggest that activin is important for endometrial repair. Interestingly, a recent study demonstrated significantly lower levels of activin A in menstrual fluid from women with dysfunctional uterine bleeding compared with healthy subjects (42).
Considering our working hypothesis that abnormal uterine bleeding is a result of impaired or incorrect endometrial repair after menses, this finding supports our data suggesting an involvement of activin in endometrial repair processes.
The tissue localisation of both βA and βB observed in this study during endometrial repair in the mouse supports the functional studies. In human endometrium, activin βA is localised to the epithelium, decidualised stromal cells and leukocytes (32, 43). Thus, its cellular localisation in the mouse model is in accord with that seen in human endometrium. In human endometrium, there is a massive influx of leukocytes into the endometrium during the pre-menstrual phase (44), with these cells believed to contribute to both the breakdown and restorative processes which can occur in different regions simultaneously.
Of these leukocytes, subpopulations of macrophages and neutrophils have been identified to express βA (43, 45). βB-positive leukocytes have also been identified in the human endometrium, primarily in the basalis region (43). A similar influx of leukocytes is also observed in the mouse model, with high numbers of these cells present during both endometrial breakdown and restoration (25). During endometrial restoration in particular, neutrophils are the most abundant leukocyte (25); thus it is highly likely that the βA-positive leukocytes observed in this study are also neutrophils, as observed in human tissue. Co-localization studies have previously identified βB-positive leukocytes detected in human endometrium as subsets of macrophages and mast cells (43).
Our inability to detect βB-positive leukocytes in this study is supported by our previous work, in which we demonstrated an absence of macrophages during endometrial breakdown and repair in the mouse model (25). Similarly, in the mouse uterus mast cells are confined to the myometrium (46). The presence of both βA and βB staining within the stromal cells of the basal zone is also suggestive of a role for activin in endometrial repair. Our previous study (26) demonstrated that cells within this compartment were proliferating, and expressed estrogen receptor α, and we postulated that it was from these cells that renewal of the stromal compartment may arise.
The significant delay in endometrial repair in FSTG animals, supports a role for endogenous activin in restorative processes.
In FSTG mice the follistatin transgene is under a keratin 14 promoter, originally designed to obtain maximal expression of follistatin transgene in the skin (8). Whilst RNase protection assays revealed the presence of transgene-derived follistatin in the brain, heart, kidney, lung and tongue (8), uterine expression was not assessed, and keratin 14 has not been previously reported as expressed in the endometrium.
Our demonstration of no change in follistatin secretion between FSTG and WT uteri cultured ex vivo supports the likelihood that the transgene is not present in the uterus. Importantly the circulating FS levels in the FSTG mice were up to 10 fold higher that of WT animals. Thus excess circulating follistatin is likely to have contributed to the significant delays in endometrial restoration. Future studies will assess the mechanisms via which the endometrial repair is altered through examination of downstream signalling pathways.
Within the endometrium, TGFβ superfamily members have been linked with roles in cell proliferation, differentiation, apoptosis and tissue remodelling (for review see (47). This study has provided some of the first functional evidence for a previously undefined role for activin A in endometrial restoration following menses. This work further contributes to our understanding of the contribution of TGFβ superfamily members to endometrial biology, and provides new insights into possible treatment options for women suffering from menstrual disorders.
Figure Legends:
Figure 1: A: Quantification of wound healing of ECC-1 cells over 6 days for control (•), activin A ( ) and epidermal growth factor ( ) treated cells. Cells were wounded on day 0 and data expressed as % repair compared to original wound size at day 0. Data represents mean ± SEM for n=16 wounds per treatment. Activin A significantly increased the % repair between day 2 to and day 6 compared to control on the same day. EGF significantly increased the % repair from day 1 to day 6 compared to control on the same day. B: Quantification of wound healing of ECC-1 cells over 6 days for control (•), activin A ( ), and activin A + follistatin (♦). Data represents mean ± SEM for n=12 wounds per treatment. Addition of follistatin to activin A significantly attenuated the activin A response from day 2-6 of culture. * = p≤ 0.05, ** = p≤0.01, ***p≤0.001. 
